Clinical Trial

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Study acronym: KIEO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103. In addition, participants will be monitored for any delays to their surgery due to the study drugs.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-08-02; most recent amendment 2026-02-27.
Status change: Not Yet Recruiting → Recruiting 2023-10-12
Trial Details
NCT Number NCT05977907
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: IO Biotech, Merck Sharp & Dohme LLC
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 30 participants
Start Date 2023-12-14
Primary Completion 2026-10-16 (estimated)
Study Completion 2028-10-16 (estimated)
Updated on ClinicalTrials.gov 2026-03-03